ISR News and Press, IsoRay Inc. From 11/10/22

IsoRay press release ( NYSE: ISR ): Q1 GAAP EPS of -$0.03 misses by $0.02 . Revenue of $1.72M (-32.8% Y/Y) misses by $1.41M . For further details see: IsoRay GAAP EPS of -$0.03 misses by $0.02, revenue of $1.72M misses by $1.41M

RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended ...

RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial r...

Summary The company's growth has stalled and its costs are increasing and it doesn't look like a dramatic reverse is in sight anytime soon. Viewpoint is promising but years off from generating revenues and only adds costs, for now. While the company still has cash to last them...

NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: BTRS Holdings Inc. (NASDAQ:BTRS)'s...

NEW YORK, NY / ACCESSWIRE / October 2, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Provident Finan...

Radiopharmaceutical company Viewpoint Molecular Targeting is set to merge with medical technology company Isoray ( NYSE: ISR ), subject to approval by the shareholders of both the companies. According to the definitive merger agreement, each issued and outstanding sha...

CORALVILLE, IA / ACCESSWIRE / September 29, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that i...

Isoray, Inc. (ISR) Q4 2022 Earnings Conference Call September 28, 2022, 4:30 PM ET Company Participants Mark Levin - Investor Relations Lori Woods - Chief Executive Officer Thijs Spoor - Chief Executive Officer, Viewpoint Molecular Targeting Jonathan Hunt - C...

IsoRay press release ( NYSE: ISR ): FQ4 GAAP EPS of -$0.01 in-line. Revenue of $2.51M (-7.4% Y/Y) misses by $0.33M . Cash, cash equivalents, and certificates of deposit at the end of the fiscal year ended June 30, 2022 totaled $55.9 million and the company had no l...